

**Qty:** 100 μg/400 μL Rabbit anti-Angiogenin **Catalog No.** 40-7600 **Lot No.** 

# Rabbit anti-Angiogenin

# FORM

This polyclonal antibody is supplied as a 400 µL aliquot at a concentration of 0.25 mg/mL in phosphate buffered saline (pH 7.4) containing 0.1% sodium azide. This antibody is epitope-affinity purified from rabbit antiserum.

## PAD: ZMD.496

## **IMMUNOGEN**

Synthetic peptide derived from the N-terminal region of the human, gorilla, and orangutan angiogenin protein, which differs from mouse by one amino acid

### SPECIFICITY

This antibody is specific for the angiogenin (Ang, RNase4, RNase5) protein. On Western blots, it identifies the target band at ~14 kDa.

# REACTIVITY

Reactivity has been confirmed with recombinant human angiogenin protein.

Sample	Western Blotting
Human	+++

(Excellent +++, Good++, Poor +, No reactivity 0, Not applicable N/A, Not Determined ND)

# USAGE

Working concentrations for specific applications should be determined by the investigator. Appropriate concentrations will be affected by several factors, including secondary antibody affinity, antigen concentration, sensitivity of detection method, temperature and length of incubations, etc. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.

Western Blotting: 1-3 µg/mL

#### STORAGE

PI407600

Store at 2-8°C for up to one month. Store at -20°C for long-term storage. Avoid repeated freezing and thawing.

(cont'd)

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

(Rev 10/08) DCC-08-1089

**Important Licensing Information** - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, <u>www.invitrogen.com</u>). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

## BACKGROUND

Angiogenesis, the process of new blood vessel formation from the established microcirculation, accounts for the formation of vasculature into previously avascular organs such as brain and kidney,<sup>1-2</sup> and is required in the adult during normal tissue repair and in the remodeling of the female reproductive organs.<sup>3</sup>

Angiogenin (Ang) is a non-glycosylated polypeptide, 123 amino acids in length, with a molecular mass of 14 kDa. It is secreted by tumor cells<sup>4</sup> and is a potent inducer of neovascularization. Angiogenin is produced by a variety of cell types including vascular endothelial cells and smooth muscle cells,<sup>5</sup> fibroblasts, tumor colonic epithelium, normal peripheral blood lymphocytes,<sup>6</sup> lung and colonic epithelial tumor cell lines,<sup>6</sup> and primary gastrointestinal adenocarcinomas.<sup>7</sup> It specifically binds to endothelial cells and elicits second messenger systems. Angiogenin is present in human follicular fluid, and its production is up-regulated by human chorionic gonadotropin and hypoxic conditions.<sup>8</sup> Angiogenin shows a high degree of homology with known ribonucleases such as pancreatic ribonuclease A,<sup>9</sup> and the capacity of angiogenin to induce blood vessel growth is dependent on its ribo-nucleolytic activity. Angiogenin is thought to be involved in the development of solid tumors; angiogenin antagonists are capable of inhibiting tumor growth. Angiogenin is endocytosed by subconfluent endothelial cells and translocated to the nucleus, where it accumulates in the nucleolus.<sup>10-11</sup> Serum angiogenin concentration is increased in serum of colorectal cancer patients, and correlates with cancer progression.<sup>12</sup> The cytoskeletal protein  $\alpha$ -actinin-2 binds to angiogenin, which might be a novel interface target for anti-angiogenesis and anti-tumor therapy.<sup>13</sup>

## REFERENCES

- 1. Cockerill GW, et al. Int Rev Cytol 159:113-160, 1995.
- 2. Diaz-Flores L, et al. Histol Histopathol 9:807-843, 1995.
- 3. Rajashekhar G, et al. Mol Reprod Dev 62:159-166, 2002.
- 4. Kurachi K, et al. *Biochemistry* 24:5494-5499, 1985.
- 5. Moenner M, et al. Eur J Biochem 226:483-490, 1994.
- 6. Rybak SM, et al. Biochem Biophys Res Commun 146:1240-1248, 1987.
- 7. Li D, et al. J Pathol 172:171-175, 1994.
- 8. Koga K, et al. J Clin Endocrinol Metab 85:3352-3355, 2000.
- 9. Archaya KR, et al. *PNAS* 91:2915-2919, 1994.
- 10. Moroianu J, et al. Biochem Biophys Res Commun 203:1765-1772, 1994.
- 11. Tsuji T, et al. Cancer Res 65:1352-1360, 2005.
- 12. Shimpyama A, et al. Clin Cancer Res 5:1125-1130, 1999.
- 13. Hu H, et al. Biochem Biophys Res Commun 329:661-667, 2005.

# **RELATED PRODUCTS**

Product	Conjugate	Cat. No.
Protein A	Sepharose <sup>®</sup> 4B	10-1041
rec-Protein G	Sepharose <sup>®</sup> 4B	10-1241

	ZyMAX™ Goat x Rabbit IgG	ZyMAX™ Goat x Mouse IgG
Conjugate	(H+L)	(H+L)
Purified	81-6100	81-6500
FITC	81-6111	81-6511
TRITC	81-6114	81-6514
Cy™3	81-6115	81-6515
Cy™5	81-6116	81-6516
HRP	81-6120	81-6520
AP	81-6122	81-6522
Biotin	81-6140	81-6540

Zymed<sup>®</sup> and ZyMAX<sup>™</sup> are trademarks of Zymed Laboratories Inc. Cy<sup>™</sup> and Sepharose<sup>®</sup> are trademarks of Amersham Biosciences Ltd.

# For Research Use Only

## www.invitrogen.com

LF050815

(Rev 10/08) DCC-08-1089

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI407600

**Important Licensing Information** - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, <u>www.invitrogen.com</u>). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.